Chemical Genomics: Undruggables and the Quest for Therapeutics

The Scientist is bringing together a panel of experts to discuss chemical genomics and the advances and promises it brings to therapeutic discovery

Apr 29, 2019
The Scientist Creative Services Team

FREE Webinar

Wednesday, August 7, 2019
2:30-4:00 PM Eastern Time
Register Now

When the human genome was mapped in the early 2000s, researchers at the time were hopeful that knowing the blueprint of every disease-causing protein in the body would swiftly lead to treatments. Although mapping the human genome did help to uncover various disease-causing proteins, almost two decades later it’s now clear that the complex biology of disease combined with the endless task of screening small molecules means many of these targets remain undruggable. However, chemical genomics, defined as the systematic screening of libraries of small molecules against various drug target families, promises hope to remedy this vast gap in therapeutics. Numerous high-throughput screening assays and chemical probes are employed in chemical genomics, many of which have been adapted from large-scale technologies within the pharmaceutical industry. To learn more about chemical genomics and the advances and promises it brings to therapeutic discovery, The Scientist is bringing together a panel of researchers in the chemical genomics field for this free educational webinar.

Topics to be covered:

  • Roadblocks and opportunities for protected open innovation in pharmaceutical R&D
  • Patient lead approaches to identify novel targets with chemical genomics

Register Now

Meet the Speakers:

Mel Reichman, PhD
Senior Investigator, Director, Chemical Genomics Center
CSO Small Molecule R&D
Lankenau Institute for Medical Research (LIMR)

John P. Overington, PhD
Chief Informatics Officer
Catapult Medicines Discovery, UK